Suman Kambhampati, MD
Hematology & Oncology · Kansas City, MONPI 1437259215
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,484 of the $30,763 with a category attached, or 79.6%. 19 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 53.1% of the total. Reporting peaked in 2019 at $15,728 and has fallen 98.7% since, to $203 in 2025. Among hematology & oncology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $809.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$16K
- Gilead$5K
- Incyte Corporation$4K
- Amgen$4K
- Foundation Medicine, Inc.$202
- Genentech, Inc.$147
- plus $747 from 13 others
Across 1,087 payments — averaging $4587.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$1.1M
- Bristol Myers Squibb$692K
- Pfizer$636K
- Beigene, Ltd.$453K
- Janssen Research & Development, LLC$277K
- E.r. Squibb & Sons, L.L.C.$258K
- plus $1.5M from 21 others
What the payments were for
- Consulting fees$24,48480%
- Speaking & faculty fees$4,18914%
- Travel & lodging$7963%
- Food & beverage$1,2674%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $16,340 |
| Gilead(2 entities) | 4 | $5,445 |
| Incyte Corporation | 2 | $3,987 |
| Amgen | 1 | $3,894 |
| Foundation Medicine, Inc. | 1 | $202 |
| Genentech, Inc. | 1 | $147 |
| ADC Therapeutics America, Inc. | 1 | $131 |
| Stemline Therapeutics Inc. | 1 | $123 |
| Sanofi | 2 | $118 |
| Johnson & Johnson | 4 | $85 |
| Akcea Therapeutics, Inc. | 1 | $80 |
| Astellas Pharma US Inc | 3 | $69 |
| Bristol Myers Squibb | 1 | $30 |
| Acrotech Biopharma Inc. | 2 | $26 |
| AstraZeneca | 1 | $23 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| Novartis | 1 | $20 |
| AbbVie | 1 | $20 |
| Pfizer | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NINLARO$16,138
- Blincyto$3,894
- Tecartus$1,700
- Yescarta$1,350
- FOUNDATIONONE$202
- FOUNDATIONONE HEME$202
- FOUNDATIONONE CDX$202
- FOUNDATIONFOCUS$202
- FOUNDATIONONE LIQUID CDX$202
- ZYNLONTA$131
- ELZONRIS$123
How this compares
$30,763 in reported general payments places this provider in the 90th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 47 | $743,651 |
| PomalystPomalidomide | 24 | $648,290 |
| ImbruvicaIbrutinib | 22 | $387,700 |
| Lenalidomide | 17 | $247,780 |
| TasignaNilotinib Hcl | 11 | $222,237 |
| BrukinsaZanubrutinib | 12 | $181,834 |
| VenclextaVenetoclax | 13 | $74,426 |
| Acyclovir | 68 | $1,202 |
| Potassium Chloride | 13 | $687 |
| Gabapentin | 31 | $484 |
| Hydroxyurea | 15 | $94 |
| Furosemide | 12 | $78 |
| Levofloxacin | 12 | $76 |
| Escitalopram Oxalate | 12 | $63 |
| Allopurinol | 18 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $30 | $743,65147 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $21 | $387,70022 claims |
| NovartisTasigna | $20 | $222,23711 claims |
| AbbVieVenclexta | $20 | $74,42613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Kansas City
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Whitney HensingKansas City$62K
- Jaswinder SinghKansas City$46K
- Nicholas ShulerKansas City$18K
- Marc RothKansas City$12K
- Tolga TuncerKansas City$10K
- Karan JosanKansas City$8K
- Maureen SheehanKansas City$8K
- David SchlossmanColumbia$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.